ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1101

Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia

Maria-Luisa Peral-Garrido1, Paula Boix-Navarro2, Silvia Gómez-Sabater3, Rocío Caño-Alameda3, Alejandra Bermúdez-García4, Teresa Lozano4, Ruth Sanchez-Ortiga4, Miguel Perdiguero4, Elena Caro-Martínez5, Carolina Ruiz-García6, Eliseo Pascual4, Rubén Francés2 and Mariano Andrés4, 1Vinalopó University Hospital, Novelda, Spain, 2Miguel Hernandez University, San Juan de Alicante, Spain, 3Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, 4Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 5San Vicente Hospital-HACLE, San Vicente del Raspeig, Spain, 6Campoamor Health Centre, Alicante, Spain

Meeting: ACR Convergence 2023

Keywords: Crystal-induced arthritis, hyperuricemia, Inflammation, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Whether the presence of subclinical monosodium urate (MSU) crystal deposition leads to a pro-inflammatory state in asymptomatic hyperuricemia (AH) is unknown. We aimed to compare the inflammatory state in peripheral blood between AH patients with and without sonographic deposits.

Methods: Observational, cross-sectional study. Patients with current serum urate ≥7 mg/dl and no history of acute arthritis were consecutively recruited from internal medicine, cardiology, nephrology, endocrinology, rheumatology, and primary care. We excluded those on urate-lowering treatment or colchicine, another inflammatory rheumatic disease, or being under immunosuppressive therapy (including transplants).

Two comparative groups were predefined. Group 1: AH without deposits; and Group 2: AH with deposits. As sonographic deposits, we considered grade 2-3 double-contour sign and/or tophus according to 2021 OMERACT definitions1, after a 10-location scanning (knees, tibiotalar joints, 1st and 2nd metatarsophalangeal joints, patellar and Achilles tendons) by a trained sonographer blinded to clinical and laboratory data. We measured serum levels of high-sensitivity C-reactive protein (hsCRP) in mg/dl (by immunoturbidimetry), serum amyloid-A in ng/ml (by nephelometry), and erythrocyte sedimentation rate (ESR) in mm/1h, as acute phase reactants. Later, using commercial ELISA kits, we analyzed: i) inflammasome NLRP3-related cytokines: interleukin (IL)-1β, IL-1 receptor antagonist (IL-1RA), IL-18, IL-18 binding protein (IL-18BP); and ii) general pro-inflammatory and anti-inflammatory cytokines: tumor necrosis factor (TNF)-α, IL-6, soluble IL-6 receptor (sIL-6R), and transforming growth factor (TGF)-β.

GraphPad Prism (version 9.5.1) was used to compare AH groups, through Mann-Whitney U’s and Chi2 tests.

Results: 77 subjects with AH were recruited, 71.4% men, with a mean age of 59.8 years (SD 17.3) and body mass index (BMI) of 31.2 kg/m2 (SD 5.2). 37.7% and 29.9% had cardiovascular (CVD) and renal disease, respectively. Their mean uric acid was 7.6 mg/dl (SD 1.6).

Patients were classified into group 1 (n=35, 45.5%) or group 2 (n=42, 54.5%). There were no differences (group 2 vs. group 1) in age (67 vs. 56 years), men (69% vs.74.3%), BMI (31.7 vs. 29.9 kg/m2), CVD (38.1% vs. 37.1%), estimated glomerular filtration rate (73.42 vs. 75.03 ml/min/1.73m2), or current serum urate levels (7.35 vs. 7.40 mg/dl). The results of inflammatory markers and cytokines are presented in Figures 1 and 2. There were no differences between groups, but we observed numerical differences for hsCRP, IL-6, and TNF-α.

Conclusion: The inflammatory state was comparable in AH between those with and without sonographic deposits. Some hints were noted for hsCRP, IL-6, and TNF-α that further studies with larger sizes must confirm to establish the relevance of subclinical crystal deposition in AH.

Reference: [1] Christiansen SN. Semin Arthritis Rheum. 2021;51:644.

Supporting image 1

Figure 1. Comparison of acute phase reactants between groups of asymptomatic hyperuricemia. Bars show medians with their 95% confidence intervals. hsCRP: high-sensitivity C reactive protein; SAA: serum A-amyloid protein; ESR: erythrocyte sedimentation rate.

Supporting image 2

Figure 2. Comparison of cytokines between groups of asymptomatic hyperuricemia. Bars show medians with their 95% confidence intervals. IL_1β: interleukin_1β; IL1_1RA: IL_1 receptor antagonist; IL_18: interleukin_18; IL_18BP: IL_18 binding protein; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6; sIL-6R: soluble IL-6 receptor; TGF-β: transforming growth factor-β.


Disclosures: M. Peral-Garrido: None; P. Boix-Navarro: None; S. Gómez-Sabater: None; R. Caño-Alameda: None; A. Bermúdez-García: None; T. Lozano: None; R. Sanchez-Ortiga: None; M. Perdiguero: None; E. Caro-Martínez: None; C. Ruiz-García: None; E. Pascual: None; R. Francés: None; M. Andrés: None.

To cite this abstract in AMA style:

Peral-Garrido M, Boix-Navarro P, Gómez-Sabater S, Caño-Alameda R, Bermúdez-García A, Lozano T, Sanchez-Ortiga R, Perdiguero M, Caro-Martínez E, Ruiz-García C, Pascual E, Francés R, Andrés M. Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/systemic-inflammation-associated-with-silent-deposition-of-monosodium-urate-crystals-in-asymptomatic-hyperuricemia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-inflammation-associated-with-silent-deposition-of-monosodium-urate-crystals-in-asymptomatic-hyperuricemia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology